000			03995nam a22003975i 4500
001			80316
003			ES-MaUEC
005			20230207040300.0
007			cr nn 008mamaa
008			140820s2014 xxu| s |||| 0|eng d
020			_a9781493911769
024	7		_a10.1007/978-1-4939-1176-9 _2doi
050		4	_aRC280.P7 _bM363 2014 EB
082	0	4	_a616.6
245	0	0	_aManagement of Castration Resistant Prostate Cancer _cedited by Fred Saad, Mario A. Eisenberger
260			_aNew York, NY _bSpringer New York _bImprint: Humana Press _c2014
300			_a1 recurso en línea (XVI, 337 p.)
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	1		_aCurrent Clinical Urology _x2197-7194
505	0		_aIntroduction - Castration Resistant Prostate Cancer: A Rapidly Expanding Clinical State and a Model for New Therapeutic Opportunities -- Evolution of Clinical States and the Castration Resistant Clinical Paradigm -- Molecular Mechanisms of Prostate Cancer Progression after Castration -- New Imaging Modalities -- Androgen Receptor Biology in Castration Resistant Prostate Cancer -- The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer -- Approaches Targeting Androgen Synthesis (CYP 17 inhibitors) -- Cytotoxic Chemotherapy (Taxanes and Taxane Combinations) -- The Emerging Role of Immunotherapy in Castrate Resistant Prostate Cancer -- Bone Targeted Therapy: Rationale and Current Status -- Radium-223 and Other Radiopharmaceuticals in Prostate Cancer -- Introduction -- Phase I/II targeted treatments -- Defining Clinical Endpoints in Castration-resistant Prostate Cancer -- Angiogenesis Inhibition in Castration Resistant Prostate Cancer -- Co-targeting Adaptive Survival Pathways -- Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer -- PARP Inhibitors -- Targeting C-Met/VEGF in Castration Resistant Prostate Cancer -- Epigenetics in Castration Resistant Prostate Cancer -- Undifferentiated Prostate Cancer and the Neuroendocrine Phenotype -- Strategies Addressing Quality of Life: Patient Reported Outcome and Symptoms Management -- Evidence-Based Therapeutic Approaches for mCRPC patients: Rational Sequence of Standard Treatment Options and Design for Future Drug Development
520			_aThis volume provides new data about the molecular biology of CRPC and a review of the definition, staging and prognostic factors that define CRPC. The book features an in-depth review of proven therapeutic options, including bone-targeted therapies, immunotherapy, chemotherapy and hormonal based therapies. Combination therapy as well as novel targeted approaches presently under investigation are also reviewed. The text provides up-to-date guidelines and algorithms for the management of CRPC based on international guidelines presently available as well as evidence-based medicine. As a concise yet comprehensive summary of the current status of the field, Management of Castration Resistant Prostate Cancer serves as a very useful resource for physicians and researchers dealing with this challenging malignancy
710	2		_aSpringerLink (Online service) _0Local _9106996
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGER
650		7	_aPróstata _xCáncer _0comprobar BNE19901355947 _2embne _9182337
700	1		_aSaad, Fred _eeditor literario _988373 _0Local
700	1		_aEisenberger, Mario A _eeditor literario _947272
830		0	_aCurrent Clinical Urology _x2197-7194 _9133629
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4939-1176-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9781493911769
907			_a.b12880693 _b10-10-17 _c11-11-15
998			_am _a_alco _a_vill _b04-04-17 _cm _dz _ek _feng _gxxu _h0
945			_aRC280.P7 M363 2014 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11560514 _z06-04-17
999			_c80316 _d80316 _x1